Research
Hormonal
Discontinuation of semaglutide or tirzepatide leads to significant weight regain, indicating that these therapies require long-term use to maintain metabolic benefits.
If you stop taking semaglutide or tirzepatide, you will likely regain most of the weight you lost. These drugs treat obesity and diabetes as chronic conditions, meaning they are meant to be taken long-term to maintain the health benefits. Stopping them reverses the progress made.
StrongQualifiesHIGH confidence
participants regained about two-thirds of the weight they had lost within a year of stopping the medication
Why this rating
Supported by STEP 1 extension and STEP 4 trial data.
Source
Semaglutide and Tirzepatide: Revolutionary Therapies for Obesity and Type 2 Diabetes Mellitus Management
James P. Torres-Pirela · Ponce Health Sciences University Scientific Journal · 2025
DOI 10.71332/ekx6t266
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →